OTTAWA, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, is pleased to announce that it has entered into a Sales and Distribution Agreement with Mr. Dennis Fowler for Vivamune within the Greater Toronto Area (GTA).
The agreement is for a minimum of six months, and includes the cities of Oakville, Mississauga, Burlington and Milton. Mr. Fowler’s compensation will be commission based and includes a retainer, the latter which shall be funded through commission sales once agreed sales targets are achieved.
Mr. Fowler is a Brand and Marketing Strategist who partners with leading edge companies to grow their brand awareness, product sales and enhance corporate presence. With over two decades of senior management positions in advertising and marketing for multimillion-dollar brands and start-ups, Dennis understands what is required for products to be noticed and is passionate about delivering effective outcomes. He appreciates the importance of connecting with one’s target audience and has the expertise to successfully communicate a compelling strategic message. Dennis has wide-ranging experience in cultivating new distribution channels and is tenacious in closing deals. He possesses a broad background in retail display and has developed powerful in-store programs for large chains such as The Home Depot.
About Avivagen Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com . The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan, Thailand and New Zealand.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s contract with Mr. Fowler may not have the anticipated effect to increase sales of Vivamune or on Vivamune’s overall sales due to many factors, many of which are outside of Avivagen’s control. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or
For more information: Avivagen Inc. Drew Basek Director of Investor Relations 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733 E-mail: d.basek@avivagen.com
Kym Anthony Chairman & Interim CEO 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164 Website: www.avivagen.com
Copyright © 2018 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
